[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100498460":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":34,"responsibleParty":402,"collaborators":404,"id":414,"slug":415,"hasResults":416,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":416,"sex":422,"minAge":32,"maxAge":32,"enrollmentInfo":423,"targetDuration":32,"studyType":426,"phases":427,"briefSummary":430,"conditions":431,"keywords":443,"overallStatus":37,"whyStopped":32,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":467},{"fullName":5,"class":6},"Cancer Research UK","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Arm 03","EXPERIMENTAL","This entrectinib treatment arm is for adult, paediatric and TYA patients with ROS1 gene fusion-positive malignancies.",[13],"Drug: Entrectinib",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Entrectinib","Adult and paediatric patients with body surface area (BSA) ≥1.51 m\\^2 will receive entrectinib orally at a dose of 600 mg daily dose (three 200 mg capsules per day).\n\nPaediatric patients with BSA \\\u003C1.51 m\\^2 will receive entrectinib at a dose of 100 mg (BSA=0.43-0.50 m\\^2) or 200 mg (BSA=0.51-0.80 m\\^2) or 300 mg (BSA=0.81-1.10 m\\^2) or 400 mg (BSA=1.11-1.50 m\\^2).\n\nEach cycle of treatment will consist of 28 days and patients may continue until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.",[9],[21],"Rozlytrek",[23],{"name":24,"affiliation":25,"role":26},"Matthew Krebs, Dr","The Christie Hospital","PRINCIPAL_INVESTIGATOR",[28],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"Aida Sarmiento Castro","CONTACT","+44 207 242 0200",null,"determine@cancer.org.uk",[35,53,68,80,95,104,119,135,147,160,175,187,202,217,232,244,256,271,281,296,311,321,336,345,360,372,387],{"facility":36,"status":37,"city":38,"state":32,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Belfast City Hospital","RECRUITING","Belfast","BT9 7AB","United Kingdom","UK",{"type":43,"coordinates":44},"Point",[45,46],-5.92541,54.59682,{"lat":46,"lon":45},[49,52],{"name":50,"role":30,"phone":32,"phoneExt":32,"email":51},"Vicky Coyle, Prof","V.Coyle@qub.ac.uk",{"name":50,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":54,"status":37,"city":55,"state":32,"zip":56,"country":40,"countryCode":41,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"University Hospital Birmingham","Birmingham","B15 2TT",{"type":43,"coordinates":58},[59,60],-1.89983,52.48142,{"lat":60,"lon":59},[63,67],{"name":64,"role":30,"phone":65,"phoneExt":32,"email":66},"Gary Middleton, Prof","0121 371 3573","G.Middleton@bham.ac.uk",{"name":64,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":69,"status":70,"city":55,"state":32,"zip":32,"country":40,"countryCode":41,"cosmosGeoPoint":71,"geoPoint":73,"contacts":74},"Birmingham Children's Hospital","NOT_YET_RECRUITING",{"type":43,"coordinates":72},[59,60],{"lat":60,"lon":59},[75,79],{"name":76,"role":30,"phone":77,"phoneExt":32,"email":78},"Gerard Millen, Dr","07921843607","g.millen@nhs.net",{"name":76,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":81,"status":37,"city":82,"state":32,"zip":83,"country":40,"countryCode":41,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Bristol Royal Hospital for Children","Bristol","BS2 8BJ",{"type":43,"coordinates":85},[86,87],-2.59665,51.45523,{"lat":87,"lon":86},[90,94],{"name":91,"role":30,"phone":92,"phoneExt":32,"email":93},"Antony Ng, Dr","0117 342 8044","Antony.Ng@uhbw.nhs.uk",{"name":91,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":96,"status":37,"city":82,"state":32,"zip":97,"country":40,"countryCode":41,"cosmosGeoPoint":98,"geoPoint":100,"contacts":101},"Bristol Haematology and Oncology Centre","BS2 8ED",{"type":43,"coordinates":99},[86,87],{"lat":87,"lon":86},[102,103],{"name":91,"role":30,"phone":92,"phoneExt":32,"email":93},{"name":91,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":105,"status":37,"city":106,"state":32,"zip":107,"country":40,"countryCode":41,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"Addenbrooke's Hospital","Cambridge","CB2 OQQ",{"type":43,"coordinates":109},[110,111],0.11667,52.2,{"lat":111,"lon":110},[114,118],{"name":115,"role":30,"phone":116,"phoneExt":32,"email":117},"Bristi Basu, Dr","01223 596105","bb313@medschl.cam.ac.uk",{"name":115,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":120,"status":37,"city":121,"state":32,"zip":122,"country":40,"countryCode":41,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"Velindre Cancer Centre","Cardiff","CF14 2TL",{"type":43,"coordinates":124},[125,126],-3.18,51.48,{"lat":126,"lon":125},[129,134],{"name":130,"role":30,"phone":131,"phoneExt":132,"email":133},"Robert Jones, Dr","02920 615888","6327","Robert.Hugh.Jones@wales.nhs.uk",{"name":130,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":136,"status":70,"city":121,"state":32,"zip":137,"country":40,"countryCode":41,"cosmosGeoPoint":138,"geoPoint":140,"contacts":141},"Cardiff Children's Hospital","CF14 4XW",{"type":43,"coordinates":139},[125,126],{"lat":126,"lon":125},[142,146],{"name":143,"role":30,"phone":144,"phoneExt":32,"email":145},"Madeline Adams, Dr","+442921842285","madeline.adams@wales.nhs.uk",{"name":143,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":148,"status":37,"city":149,"state":32,"zip":150,"country":40,"countryCode":41,"cosmosGeoPoint":151,"geoPoint":155,"contacts":156},"Western General Hospital","Edinburgh","EH4 2XU",{"type":43,"coordinates":152},[153,154],-3.19648,55.95206,{"lat":154,"lon":153},[157,159],{"name":158,"role":30,"phone":32,"phoneExt":32,"email":32},"Stefan Symeonides, Dr",{"name":158,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":161,"status":37,"city":162,"state":32,"zip":163,"country":40,"countryCode":41,"cosmosGeoPoint":164,"geoPoint":168,"contacts":169},"The Beatson Hospital","Glasgow","G12 OYN",{"type":43,"coordinates":165},[166,167],-4.25763,55.86515,{"lat":167,"lon":166},[170,174],{"name":171,"role":30,"phone":172,"phoneExt":32,"email":173},"Patricia Roxburgh, Dr","0141 301 7118","Patricia.Roxburgh@glasgow.ac.uk",{"name":171,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":176,"status":37,"city":162,"state":32,"zip":177,"country":40,"countryCode":41,"cosmosGeoPoint":178,"geoPoint":180,"contacts":181},"Royal Hospital for Children Glasgow","G51 4TF",{"type":43,"coordinates":179},[166,167],{"lat":167,"lon":166},[182,186],{"name":183,"role":30,"phone":184,"phoneExt":32,"email":185},"Milind Ronghe, Dr","0141 452 6692","Milind.Ronghe@ggc.scot.nhs.uk",{"name":183,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":188,"status":37,"city":189,"state":32,"zip":190,"country":40,"countryCode":41,"cosmosGeoPoint":191,"geoPoint":195,"contacts":196},"Leicester Royal Infirmary","Leicester","LE1 5WW",{"type":43,"coordinates":192},[193,194],-1.13169,52.6386,{"lat":194,"lon":193},[197,201],{"name":198,"role":30,"phone":199,"phoneExt":32,"email":200},"Olubukola Ayodele, Dr","0116 2587601","olubukola.ayodele@uhl-tr.nhs.uk",{"name":198,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":203,"status":37,"city":204,"state":32,"zip":205,"country":40,"countryCode":41,"cosmosGeoPoint":206,"geoPoint":210,"contacts":211},"Alder Hey Hospital","Liverpool","L14 5AB",{"type":43,"coordinates":207},[208,209],-2.97794,53.41058,{"lat":209,"lon":208},[212,216],{"name":213,"role":30,"phone":214,"phoneExt":32,"email":215},"Lisa Howell, Dr","0151 293 3679","Lisa.Howell@alderhey.nhs.uk",{"name":213,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":218,"status":37,"city":219,"state":32,"zip":220,"country":40,"countryCode":41,"cosmosGeoPoint":221,"geoPoint":225,"contacts":226},"University College London Hospital","London","NW1 2BU",{"type":43,"coordinates":222},[223,224],-0.12574,51.50853,{"lat":224,"lon":223},[227,231],{"name":228,"role":30,"phone":229,"phoneExt":32,"email":230},"Martin Forster, Prof","020 3447 5085","M.Forster@ucl.ac.uk",{"name":228,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":233,"status":37,"city":219,"state":32,"zip":234,"country":40,"countryCode":41,"cosmosGeoPoint":235,"geoPoint":237,"contacts":238},"Guy's Hospital","SE1 9RT",{"type":43,"coordinates":236},[223,224],{"lat":224,"lon":223},[239,243],{"name":240,"role":30,"phone":241,"phoneExt":32,"email":242},"James Spicer, Dr","020 7188 4260","james.spicer@kcl.ac.uk",{"name":240,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":245,"status":37,"city":219,"state":32,"zip":246,"country":40,"countryCode":41,"cosmosGeoPoint":247,"geoPoint":249,"contacts":250},"Great Ormond Street Hospital","WC1N 3JH",{"type":43,"coordinates":248},[223,224],{"lat":224,"lon":223},[251,255],{"name":252,"role":30,"phone":253,"phoneExt":32,"email":254},"Darren Hargrave, Dr","0207 813 8525","Darren.hargrave@gosh.nhs.uk",{"name":252,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":257,"status":70,"city":258,"state":32,"zip":259,"country":40,"countryCode":41,"cosmosGeoPoint":260,"geoPoint":264,"contacts":265},"Royal Manchester Children's Hospital","Manchester","M13 9WL",{"type":43,"coordinates":261},[262,263],-2.23743,53.48095,{"lat":263,"lon":262},[266,270],{"name":267,"role":30,"phone":268,"phoneExt":32,"email":269},"Guy Makin, Dr","0161 701 8419","Guy.Makin@mft.nhs.uk",{"name":267,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":25,"status":37,"city":258,"state":32,"zip":272,"country":40,"countryCode":41,"cosmosGeoPoint":273,"geoPoint":275,"contacts":276},"M20 4BX",{"type":43,"coordinates":274},[262,263],{"lat":263,"lon":262},[277,280],{"name":24,"role":30,"phone":278,"phoneExt":32,"email":279},"0161 918 7672","matthew.krebs@nhs.net",{"name":24,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":282,"status":37,"city":283,"state":32,"zip":284,"country":40,"countryCode":41,"cosmosGeoPoint":285,"geoPoint":289,"contacts":290},"Clatterbridge Cancer Centre","Metropolitan Borough of Wirral","CH63 4JY",{"type":43,"coordinates":286},[287,288],-3.10501,53.37616,{"lat":288,"lon":287},[291,295],{"name":292,"role":30,"phone":293,"phoneExt":32,"email":294},"Dan Palmer, Dr","0151 706 4172 \u002F 0151 706 4177","daniel.palmer@liverpool.ac.uk",{"name":292,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":297,"status":37,"city":298,"state":32,"zip":299,"country":40,"countryCode":41,"cosmosGeoPoint":300,"geoPoint":304,"contacts":305},"Great North Children's Hospital","Newcastle","NE1 4LP",{"type":43,"coordinates":301},[302,303],-5.88979,54.21804,{"lat":303,"lon":302},[306,310],{"name":307,"role":30,"phone":308,"phoneExt":32,"email":309},"Alastair Greystoke, Dr","0191 2138476","Alastair.Greystoke@newcastle.ac.uk",{"name":307,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":312,"status":37,"city":298,"state":32,"zip":313,"country":40,"countryCode":41,"cosmosGeoPoint":314,"geoPoint":316,"contacts":317},"Freeman Hospital","NE7 7DN",{"type":43,"coordinates":315},[302,303],{"lat":303,"lon":302},[318,320],{"name":307,"role":30,"phone":308,"phoneExt":32,"email":319},"Greystoke@newcastle.ac.uk",{"name":307,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":322,"status":37,"city":323,"state":32,"zip":324,"country":40,"countryCode":41,"cosmosGeoPoint":325,"geoPoint":329,"contacts":330},"Churchill Hospital","Oxford","OX3 7LE",{"type":43,"coordinates":326},[327,328],-1.25596,51.75222,{"lat":328,"lon":327},[331,335],{"name":332,"role":30,"phone":333,"phoneExt":32,"email":334},"Sarah Pratap, Dr","01865 235273","Sarah.Pratap@ouh.nhs.uk",{"name":332,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":337,"status":37,"city":323,"state":32,"zip":338,"country":40,"countryCode":41,"cosmosGeoPoint":339,"geoPoint":341,"contacts":342},"John Radcliffe Hospital","OX3 9DU",{"type":43,"coordinates":340},[327,328],{"lat":328,"lon":327},[343,344],{"name":332,"role":30,"phone":333,"phoneExt":32,"email":334},{"name":332,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":346,"status":37,"city":347,"state":32,"zip":348,"country":40,"countryCode":41,"cosmosGeoPoint":349,"geoPoint":353,"contacts":354},"Weston Park Hospital","Sheffield","S10 2SJ",{"type":43,"coordinates":350},[351,352],-1.4659,53.38297,{"lat":352,"lon":351},[355,359],{"name":356,"role":30,"phone":357,"phoneExt":32,"email":358},"Sarah Danson, Dr","0114 226 5068","s.danson@sheffield.ac.uk",{"name":356,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":361,"status":37,"city":347,"state":32,"zip":362,"country":40,"countryCode":41,"cosmosGeoPoint":363,"geoPoint":365,"contacts":366},"Sheffield's Children's Hospital","S10 2TH",{"type":43,"coordinates":364},[351,352],{"lat":352,"lon":351},[367,371],{"name":368,"role":30,"phone":369,"phoneExt":32,"email":370},"Daniel Yeomanson, Dr","01142717366","danyeomanson@nhs.net",{"name":368,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":373,"status":37,"city":374,"state":32,"zip":375,"country":40,"countryCode":41,"cosmosGeoPoint":376,"geoPoint":380,"contacts":381},"Southampton General Hospital","Southampton","SO16 6YD",{"type":43,"coordinates":377},[378,379],-1.40428,50.90395,{"lat":379,"lon":378},[382,386],{"name":383,"role":30,"phone":384,"phoneExt":32,"email":385},"Juliet Gray, Prof","0238 120 6639","Juliet.Gray@uhs.nhs.uk",{"name":383,"role":26,"phone":32,"phoneExt":32,"email":32},{"facility":388,"status":37,"city":389,"state":32,"zip":390,"country":40,"countryCode":41,"cosmosGeoPoint":391,"geoPoint":395,"contacts":396},"The Royal Marsden Hospital","Sutton","SM2 5PT",{"type":43,"coordinates":392},[393,394],-0.2,51.35,{"lat":394,"lon":393},[397,401],{"name":398,"role":30,"phone":399,"phoneExt":32,"email":400},"Lynley Marshall, Dr","0208 661 3678","LynleyVanessa.Marshall@icr.ac.uk",{"name":398,"role":26,"phone":32,"phoneExt":32,"email":32},{"type":403,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[405,407,409,411],{"name":406,"class":6},"University of Manchester",{"name":408,"class":6},"University of Birmingham",{"name":410,"class":6},"Royal Marsden NHS Foundation Trust",{"name":412,"class":413},"Hoffmann-La Roche","INDUSTRY","100498460","phase-2-determine-trial-treatment-arm-03-entrectinib-in-adult-paediatric-and-teenageyoung-adult-patients-with-ros1-gene-fusion-positive-cancers-100498460",false,"NCT05770544","DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage\u002FYoung Adult Patients With ROS1 Gene Fusion-Positive Cancers.","DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage\u002FYoung Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage\u002FYoung Adult Patients With ROS1 Gene Fusion-Positive Cancers.","DETERMINE","THE PATIENT MUST FULFIL THE ELIGIBILITY CRITERIA WITHIN THE DETERMINE MASTER PROTOCOL (NCT05722886) AND WITHIN THE TREATMENT ARM 03 (ENTRECTINIB) OUTLINED BELOW\\*\n\n\\*When entrectinib-specific inclusion\u002Fexclusion criteria or precautions below differ from those specified in the Master Protocol, the entrectinib-specific criteria will take precedence.\n\nInclusion Criteria:\n\nA. Confirmed diagnosis of a ROS1 gene fusion-positive malignancy, other than NSCLC, that has been identified using an analytically validated next-generation sequencing method.\n\nB. Patients must be able and willing to undergo a fresh tissue biopsy at baseline and blood samples for translational research. Note that for patients with haematological malignancies or neuroblastomas, blood, bone marrow aspiration and\u002For trephine or lymph node biopsy samples may be taken.\n\nC. Patients with a BSA of 0.43m\\^2 and over.\n\nD. ADULT PATIENTS (≥18 years): Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol. These measurements should be performed to confirm the patient's eligibility.\n\nE. PAEDIATRIC PATIENTS (\\\u003C18 years): Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol. These measurements should be performed to confirm the patient's eligibility.\n\nF. Women of childbearing potential are eligible provided that they meet the following criteria:\n\n* Have a negative serum or urine pregnancy test before enrolment and either:\n* Agree to use one form of highly effective birth control method such as:\n\nI. Oral, intravaginal or transdermal combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation\n\nII. Oral, injectable or implantable progestogen-only hormonal contraception associated with inhibition of ovulation\n\nIII. Intrauterine device (IUD)\n\nIV. Intrauterine hormone-releasing system (IUS)\n\nV. Bilateral tubal occlusion\n\nVI. Vasectomised partner\n\nPlus a barrier method if using a hormonal method: male or female condom with or without spermicide; cap, diaphragm or sponge with spermicide OR\n\n• Sexual abstinence;\n\nEffective from the first administration of entrectinib, throughout the trial and for five weeks after the last administration of entrectinib.\n\nG. Male patients with partners who are women of childbearing potential are eligible provided that they agree to the following, from the first administration of entrectinib, throughout the trial and for three months after the last administration of entrectinib:\n\n* Agree to take measures not to father children by using a barrier method of contraception (condom plus spermicide) or to sexual abstinence.\n* Non-vasectomised male patients with partners who are women of childbearing potential must also be willing to ensure that their partner uses a highly effective method of contraception as in F above.\n* Male patients with pregnant or lactating partners must be advised to use barrier method contraception (e.g. condom) to prevent drug exposure of the foetus or neonate.\n\nAll male patients must refrain from donating sperm for the same period.\n\nExclusion Criteria:\n\nA. Female patients who are pregnant, breastfeeding or planning to become pregnant during the trial or within five weeks following their last dose of entrectinib\n\nB. Diagnosis of ROS1 fusion-positive NSCLC\n\nC. Prior treatment with the same class of drug unless genetic profile demonstrates a mechanism of resistance known to be potentially sensitive to entrectinib\n\nD. Patients with significant cardiovascular disease are excluded as defined by:\n\ni. Current congestive heart failure requiring therapy (New York Heart Association III or IV) or known left ventricular ejection fraction (LVEF) \\\u003C50% (moderate to severe).\n\nii. History of unstable angina pectoris or myocardial infarction up to three months prior to trial entry, or current poorly controlled angina (symptoms weekly or more).\n\niii. Presence of symptomatic or severe valvular heart disease (severe by local echo graphic criteria or American Heart Association\u002FAmerican Cardiac College Stage C or D).\n\niv. History of a clinically significant cardiac arrhythmia up to three months prior to trial entry (asymptomatic atrial fibrillation or asymptomatic first-degree heart block are permitted.\n\nv. History of stroke (ischaemic or haemorrhagic) within the last three months.\n\n• Patients with primary CNS tumours may be considered unless intra-tumoural bleeding has occurred within 2 weeks of the first dose of entrectinib, and patients with punctate CNS haemorrhages \\\u003C3 mm may be considered.\n\nE. Patients with a baseline QTcF (Corrected QT interval by Fridericia formula) interval longer than 450 milliseconds (ms) for male patients and 470 ms for female patients, patients with congenital long QTcF syndrome, and patients taking medicinal products that are known to prolong the QTc interval.\n\nF. History of additional risk factors for Torsades de Pointes (e.g., family history of long QT syndrome)\n\nG. Grade ≥2 peripheral neuropathy\n\nH. Known active infections (bacterial, fungal or viral) that would interfere with the assessment of safety or efficacy of entrectinib, including human immunodeficiency virus (HIV) positivity. Patients with history of testing positive for HIV infection are eligible provided the each of the following conditions are met:\n\n* CD4 count ≥350\u002FμL;\n* undetectable viral load;\n* receiving antiretroviral therapy (ART) that does not interact with IMP (patients should be on established ART for at least four weeks); and\n* no HIV\u002F acquired immune deficiency syndrome (AIDS)-associated opportunistic infection in the last 12 months.\n\nI. Known hypersensitivity to entrectinib or any of the excipients\n\nJ. Patients who were administered a live, attenuated vaccine within 28 days prior to enrolment, or anticipation of need for such a vaccine during entrectinib treatment or within six months after the final dose of entrectinib\n\nK. Patient unable to swallow entrectinib intact, without chewing, crushing or opening the capsules (as per the dosing schedule and suitable dosing strengths available). Any active gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would reasonably affect drug absorption\n\nL. Patients with personal history of significant osteopenia (screening for osteopenia not required)\n\nM. Any clinically significant concomitant disease or condition (or its treatment) that could interfere with the conduct of the trial or absorption of oral medications that would, in the opinion of the Investigator, pose an unacceptable risk to the patient in this trial","ALL",{"count":424,"type":425},30,"ESTIMATED","INTERVENTIONAL",[428,429],"PHASE2","PHASE3","This clinical trial is looking at a drug called entrectinib. Entrectinib is approved as standard of care treatment for adult patients with non-small cell lung cancer (NSCLC) which have a particular molecular alteration called ROS1-positive, and patients 12 years old or above with solid tumours which have another type of change in the cancer cells. This means it has gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK.\n\nInvestigators now wish to find out if it will be useful in treating patients with other cancer types which have the same molecular alteration (ROS1-positive). If the results are positive, the study team will work with the NHS and the Cancer Drugs Fund to see if these drugs can be routinely accessed for patients in the future.\n\nThis trial is part of a trial programme called DETERMINE. The programme will also look at other anti-cancer drugs in the same way, through matching the drug to rare cancer types or ones with specific mutations.",[432,433,434,435,436,437,438,439,440,441,442],"Haematological Malignancy","Malignancy","Malignant Neoplasm","Lymphoproliferative Disorders","Neoplasms by Histologic Type","Neoplasms by Site","Cancer","Brain Neoplasms","Melanoma","Glioma","Solid Tumour",[444,445,438,446,17,433,447,448,449,450,437,451,452,453,454,455,456,457],"Adult","Antineoplastic Agents","Child","Malignant Neoplasms","Molecular Targeted Therapy","Mutation","Neoplasms by Histologic Site","Oncogene","Paediatric","Protein Kinase Inhibitors","Rare","ROS1 Protein, human","Tumour-agnostic","Young adult","2025-11-19",{"date":460,"type":461},"2025-11-24","ACTUAL",{"date":463,"type":425},"2025-11-30",{"date":465,"type":425},"2029-10",{"name":5,"class":6},27]